Viridian CFO corrects reported share ownership

Viridian Therapeutics’ Chief Financial Officer Seth Harmon filed an amended Form 4 to correct his reported share ownership.

Rhea-AI Filing Summary

Viridian Therapeutics’ Chief Financial Officer Seth Harmon filed an amended Form 4 to correct his reported share ownership. The amendment explains that a prior Form 4 filed on March 4, 2025 inadvertently omitted 1,711 shares purchased under the Viridian Therapeutics, Inc. 2016 Employee Stock Purchase Plan.

After reflecting these previously purchased shares, Harmon is shown as directly beneficially owning 1,711 shares of Viridian Therapeutics common stock. The filing does not report any new transactions, but updates the accuracy of his disclosed holdings.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Harmon Seth

Role Chief Financial Officer

Type	Security	Shares	Price	Value
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 1,711 shares (Direct)

Footnotes (1)

1. F1. This amendment is being filed to correct the number of shares beneficially owned by the Reporting Person as reported in the original Form 4 filed with the Securities and Exchange Commission on March 4, 2025, which inadvertently omitted an aggregate of 1,711 shares purchased under the Viridian Therapeutics, Inc. 2016 Employee Stock Purchase Plan.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Viridian Therapeutics (VRDN) CFO’s latest Form 4/A report?

The Form 4/A reports a correction to CFO Seth Harmon’s beneficial ownership. It adds 1,711 previously omitted common shares purchased under Viridian’s 2016 Employee Stock Purchase Plan, updating his directly held stake to reflect these shares.

How many additional Viridian Therapeutics (VRDN) shares are reflected in this Form 4/A?

The amendment reflects an additional 1,711 common shares. These shares were previously purchased under the Viridian Therapeutics, Inc. 2016 Employee Stock Purchase Plan but were inadvertently left out of Harmon’s original Form 4 filed on March 4, 2025.

Does the Viridian Therapeutics (VRDN) Form 4/A show new insider buying or selling?

The amendment does not show new buying or selling activity. Instead, it corrects past disclosure by adding 1,711 common shares previously purchased under the 2016 Employee Stock Purchase Plan that were omitted from the original March 4, 2025 Form 4.

Who filed the amended Form 4/A for Viridian Therapeutics (VRDN)?

Viridian Therapeutics’ Chief Financial Officer, Seth Harmon, filed the amended Form 4/A. He is correcting his reported beneficial ownership to include 1,711 common shares bought earlier through the company’s 2016 Employee Stock Purchase Plan.

What plan is referenced in Viridian Therapeutics (VRDN) CFO’s Form 4/A amendment?

The amendment references the Viridian Therapeutics, Inc. 2016 Employee Stock Purchase Plan. It states that 1,711 shares acquired under this plan were inadvertently omitted from the original Form 4 and are now included in Harmon’s beneficial ownership.

What was wrong with the original Viridian Therapeutics (VRDN) Form 4 filed March 4, 2025?

The original Form 4 inadvertently omitted 1,711 common shares. These shares had been purchased under the Viridian Therapeutics, Inc. 2016 Employee Stock Purchase Plan, and the Form 4/A amendment updates Seth Harmon’s beneficial ownership to include them.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/04/2026 - 07:13 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Harmon Seth

(Last) (First) (Middle)

C/O VIRIDIAN THERAPEUTICS, INC.

221 CRESCENT STREET, SUITE 103A

(Street)

WALTHAM MA 02453

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Viridian Therapeutics, Inc.\DE [ VRDN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)
03/04/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)								1,711	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This amendment is being filed to correct the number of shares beneficially owned by the Reporting Person as reported in the original Form 4 filed with the Securities and Exchange Commission on March 4, 2025, which inadvertently omitted an aggregate of 1,711 shares purchased under the Viridian Therapeutics, Inc. 2016 Employee Stock Purchase Plan.

	/s/Jennifer Tousignant, Attorney-in-fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.